Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464099 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01464099 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 24 participants.
The verdict
NCT01464099, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.
Interventions
- DRUG insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464099
The ClinicalTrials.gov registry entry for NCT01464099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin aspart is the first listed.
NCT01464099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464099 about?
NCT01464099 is a clinical study titled "Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes". This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.
What is the current status of trial NCT01464099?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-06. Estimated completion is 2008-11.
What interventions are being tested in trial NCT01464099?
The interventions under investigation include: insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01464099?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.